Background: Prurigo nodularis (PN) is an intensively pruritic skin disease that negatively influences quality of life. Cryosim-1 (Intrinsic IB Spot) is a synthetic, selective transient receptor potential melastatin 8 agonist.

Aims: To investigate the efficacy and safety of cryosim-1 in PN patients.

Patients/methods: A randomized, double-blinded, placebo-controlled clinical trial including 30 patients was conducted. The numerical rating scale (NRS) of pruritus was evaluated before and 2 h after cryosim-1 application at every visit.

Results: At week 8, the mean pruritus NRS before serum application (4.7 ± 0.4 treatment, 6.1 ± 0.5 placebo; p = 0.045) and 2 h after serum application (2.8 ± 0.4 treatment, 4.3 ± 0.5 placebo; p = 0.031) were significantly lower in the treatment group, and the mean NRS for sleep disorder was significantly lower in the treatment group (2.2 ± 0.5 treatment, 4.2 ± 0.8 placebo; p = 0.031). The mean satisfaction scales for pruritus improvement were significantly higher in the treatment group (7.2 ± 0.6) than in the placebo group (4.0 ± 0.9; p = 0.005). There was no difference in TEWL between the two groups, and no adverse reactions were reported.

Conclusions: Cryosim-1 is a safe and effective topical treatment for PN patients.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jocd.16079DOI Listing

Publication Analysis

Top Keywords

treatment group
12
randomized double-blinded
8
clinical trial
8
prurigo nodularis
8
serum application
8
placebo p = 0031
8
lower treatment
8
treatment
7
cryosim-1
5
double-blinded vehicle-controlled
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!